

IDF EUROPE SOURCES OF FUNDING 2024

Industry related income – Unrestricted funding & project support		
Name of company/funder	Amount of income	% of overall income
Air Liquide	€ 66,945.00	6.69%
Bayer	€ 30,985.00	3.10%
Boehringer Ingelheim	€ 85,648.00	8.56%
Dexcom	€ 30,000.00	3.00%
Eli Lilly	€ 275,442.00	27.53%
Abbott	€ 11,983.00	1.20%
Novo Nordisk	€ 98,850.00	9.88%
Roche Diabetes care	€ 30,000.00	3.00%
Sanofi	€ 50,000.00	5.00%
EFPIA	€ 35,000.00	3.50%
Vertex	€ 12,500.00	1.25%
Medtronic	€ 52,681.00	5.27%
Subtotal	€ 780,034.00	78%
Other income		
Source of funding	Amount of income	% of overall income
Membership/IDF grant	€ 14,056.00	1.40%
NGO funding – European Diabetes Forum (EUDF)	€ 15,000.00	1.50%
NGO funding – Associazione Medici Diabetologi (AMD)	€ 10,000.00	1.00%
EU funded project – Trials@home	€ 41,143.00	4.11%
EU funded project – Recognised	€ 4,250.00	0.42%
EU funded project – DiAPS	€ 8,813.00	0.88%
EU funded project – Islet	€ 39,044.00	3.90%
EU funded project – Digicare4You	€ 34,072.00	3.41%
Healthy food healthy planet Funded project	€ 36,105.00	3.61%
EU funded project – Assess DHT	€ 11,365.00	1.14%
EU funded project – Smart diabetes	€ 3,177.00	0.32%
EU funded project – Moveup	€ 147.00	0.01%
EU funded project - PRIME	€ 3,258.00	0.33%
Subtotal	€ 220,430.00	22%
	€ 1,000,464.00	100%